Published online before print December 12, 2002, doi: 10.1161/01.RES.0000051884.27117.7E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 19, 2002
Revised on November 27, 2002
Accepted on November 27, 2002
Relaxin, a Pregnancy Hormone, Is a Functional Endothelin-1 Antagonist. Attenuation of Endothelin-1-Mediated Vasoconstriction by Stimulation of Endothelin Type-B Receptor Expression via ERK-1/2 and Nuclear Factor-
B
Thomas Dschietzig *;
From Medizinische Klinik und Poliklinik (Kardiologie, Angiologie, Pulmologie) Charité, Campus Mitte, Berlin, Germany.
* To whom correspondence should be addressed. E-mail: AnneDsch{at}aol.com.
We have recently demonstrated that relaxin (RLX) acts as compensatory mediator in human heart failure. RLX inhibits the stimulation of endothelin-1, the most potent vasoconstrictor in heart failure. Upregulation of the endothelin type-B receptor (ETB), which mediates endothelin-1 clearance and endothelial release of NO, represents a pivotal mode of RLX action. However, signal transduction and abundance of this phenomenon are unknown. Therefore, we investigated RLX-induced regulation of ETB in human umbilical vein endothelial, epithelial (HeLa), and vascular smooth muscle cells. In human umbilical vein endothelial cells and HeLa cells, but not in human vascular smooth muscle cells, RLX upregulated ETB expression and activated extracellular signal-regulated kinase-1/2 (ERK-1/2) and nuclear factor-
B (NF-B), a transcription factor. PD-98059, a selective inhibitor of the mitogen-activated protein kinase kinase-1 (MEK-1)-ERK-1/2 pathway, abolished ERK-1/2 and NF-B activation and ETB upregulation. NF-B inhibition also prevented RLX-mediated ETB stimulation. In NF-B-luciferase reporter assays, we demonstrated complete inhibition of RLX-induced NF-B activation in cells transfected with dominant-negative Raf-1, MEK-1, or ERK-1/2 constructs, whereas dominant-negative Ras had no effect. In rat aorta and mesenteric artery, RLX pretreatment, in an ETB-dependent fashion, mitigated the maximum contractile response to endothelin-1, by 38±4% and 43±6%, and the endothelin-1 sensitivity (-log[EC50]: aorta, 8.2±0.2 for vehicle versus 7.2±0.2 for RLX; mesenteric artery, 8.0±0.2 for vehicle versus 7.1±0.1 for RLX). RLX pretreatment augmented the dilator effect of the ETB agonist endothelin-3 by 100±8% and 133±13%. In conclusion, RLX stimulates endothelial and epithelial ETB via a Ras-independent Raf-1-MEK-1-ERK-1/2 pathway that activates NF-B. On vascular smooth muscle cells, ETB, a contributor to endothelin-mediated vasoconstriction, remains unaffected. This renders RLX a functional endothelin-1 antagonist.
Key words: endothelin • receptors • signal transduction • vasoconstriction • vasodilation
This article has been cited by other articles:
 |
|
 |
|
  A. Yogi, G.E. Callera, A.C.I. Montezano, A.B. Aranha, R.C. Tostes, E.L. Schiffrin, and R.M. Touyz Endothelin-1, but not Ang II, Activates MAP Kinases Through c-Src-Independent Ras-Raf-Dependent Pathways in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1960 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-Y. Ho, W. Yan, and C. A. Bagnell Relaxin-induced matrix metalloproteinase-9 expression is associated with activation of the NF-{kappa}B pathway in human THP-1 cells J. Leukoc. Biol., May 1, 2007; 81(5): 1303 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Halls, R. A. D. Bathgate, and R. J. Summers Comparison of Signaling Pathways Activated by the Relaxin Family Peptide Receptors, RXFP1 and RXFP2, Using Reporter Genes J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 281 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Bathgate, R. Ivell, B. M. Sanborn, O. D. Sherwood, and R. J. Summers International Union of Pharmacology LVII: Recommendations for the Nomenclature of Receptors for Relaxin Family Peptides. Pharmacol. Rev., March 1, 2006; 58(1): 7 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Samuel Relaxin: Antifibrotic Properties and Effects in Models of Disease Clin. Med. Res., November 1, 2005; 3(4): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Q. Wu and W. C. Aird Thrombin, TNF-{alpha}, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H873 - H885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Kerchner, J. Novak, K. Hanley-Yanez, K. D. Doty, L. A. Danielson, and K. P. Conrad Evidence against the Hypothesis that Endothelial Endothelin B Receptor Expression Is Regulated by Relaxin and Pregnancy Endocrinology, June 1, 2005; 146(6): 2791 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.S. Hayes, E.C. Curnow, A.O. Trounson, L.A. Danielson, and E.N. Unemori Implantation and Pregnancy Following In Vitro Fertilization and the Effect of Recombinant Human Relaxin Administration in Macaca fascicularis Biol Reprod, November 1, 2004; 71(5): 1591 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Samuel, E. N. Unemori, I. Mookerjee, R. A. D. Bathgate, S. L. Layfield, J. Mak, G. W. Tregear, and X.-J. Du Relaxin Modulates Cardiac Fibroblast Proliferation, Differentiation, and Collagen Production and Reverses Cardiac Fibrosis in Vivo Endocrinology, September 1, 2004; 145(9): 4125 - 4133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Conrad and J. Novak Emerging role of relaxin in renal and cardiovascular function Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R250 - R261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. D. Sherwood Relaxin's Physiological Roles and Other Diverse Actions Endocr. Rev., April 1, 2004; 25(2): 205 - 234. [Abstract] [Full Text] [PDF]
|
|